Omega 3 fatty acid and the resolution of inflammatory processes;Papel pel dos ácidos graxos ômega 3 na resolução dos processos inflamatórios

Medicina

Volumn 44, Issue 3, 2011, Pages 224-230

  Barbalho, Sandra Maria ^a,b   Bechara, Marcelo D ^a   Quesada, Karina R ^c   Goulart, Ricardo A ^d  

^a FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

^b Faculdade de Tecnologia de Alimentos   (Brazil)

^c Faculdade de Ciencias   (Brazil)

^d FAMEMA   (Brazil)

Author keywords

Fatty acids, omega 3; Inflammation; Protectins; Resolvins

Indexed keywords

CD59 ANTIGEN; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; PROSTAGLANDIN;

CELL MEMBRANE; INFECTION; INFLAMMATION; INJURY; REVIEW;

EID: 84856119744     PISSN: 00766046     EISSN: 21767262     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Calder PC. N-3 polyunsaturated fatty acids, inflammation and inflamatory diseases. Am J Clin Nutr 2006 (83): 1505S-19S. (Pubitemid 44713092)
2. Seki H, Tani Y, Arita M. Omega3 PUFA derived anti-inflammatory lipid mediator resolving E1. Prostaglandins other lipid mediat 2009; 89:126-30.
3. Voltarelli JC. Febre e inflamação. Medicina (Ribeirão Preto) 1994; 27: 7-48.
4. Vannuchi H, Moreira EAM, Cunha DF, Junqueira-Franco MVM, Bernardes MM; Jordão-Jr AA. Papel dos nutrientes na peroxidação lipídica e no sistema de defesa antioxidante. Medicina Ribeirão Preto 1998; 31: 31-44.
5. Cardoso, LM, Colombari DAS, Menani JV, De Paula PM, Chianca DA, Colombari E. Espécies reativas de oxigênio no controle neurovegetativo da pressão arterial. Medicina (Ribeirão Preto) 2006; 39: 77-88.
6. Flower RJ. Prostaglandins, bioassay and inflammation. Br J Pharmacol 2006; 147 (Suppl 1): 182-92.
7. Serhan CN, Chiang N. Endogenous pro-resolving and antiinflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008;153 (Suppl 1): 200-15.
8. Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Inflammatory systemic biomarkers in setting acute coronary syndromes - effects of the diurnal variation. Curr Drug Targets 2009; 10:1001-8.
9. Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. Clin Chim Acta 2010; 411:785- 93.
10. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461:1287-91.
11. Chan MM, Moore AR. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by Prostaglandin E(2)-mediated lipoxin A(4) production. J Immunol 2010; 184:6418-26.
12. Persson CG, Uller L. Resolution of cell-mediated airways diseases. Respir Res 2010; 11:75.
13. Levy BD. Resolvins and protectins: natural pharmacophores for resolution biology. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 327-32.
14. Devchand PR, Schmidt BA, Primo VC, Zhang QY, Arnaout MA, Serhan CN, Nikolic B. A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. Faseb J 2005; 19:203-10 (Pubitemid 40189261)
15. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201:713-22. (Pubitemid 40395117)
16. Bueno-Jr CRB. Relevância e tratamento das lesões características da insuficiência cardíaca na musculatura esquelética. Medicina Ribeirão Preto 2009; 42: 437-50.
17. Hersberger M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin Chem Lab Med 2010; 48: 1063-73.
18. Gilroy DW, Lawrence T, Perrettti M, Rossi AG. Inflammation, resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401-16. (Pubitemid 38618123)
19. Tull SP, Yates CM, Maskrey BH, O'Donnell VB, Madden J, Grimble RF, Calder PC, Nash GB, Rainger GE. Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. Plos Biol 2009; 7: e1000177.
20. Hunter JE, Zhang J, Kris-Etherton PM. Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. Am J Clin Nutr 2010; 91: 46-63.
21. Calder, PC. Immunomodulation by omega 3 fatty acids. Prost Leukotrienes and essential fatty acids 2007; 77: 327-35.
22. Calder PC. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009; 91:791-5.
23. Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009; 121:148-57.
24. Calder PC, Yaqoob P.Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors 2009; 35:266-72.
25. Lund T, Mangsbo SM, Scholz H, Gjorstrup P, Tötterman TH, Korsgren O, Foss A. Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp Clin Endocrinol Diabetes 2010; 118: 237-44.
26. He K, Song Y, Daviglus ML, Liu K, Van Horn L. Accumulated evidence of fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004; 109: 2705-11. (Pubitemid 38737914)
27. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206:15-23.
28. Seki H, Sasaki T, Ueda T, Arita M. Resolvins as regulators of the immune system. Scientific World Journal 2010; 10:818- 31.
29. Martin CA, Almeida VV, Ruiz MR, Visentainer JEL, Matshushita M, Souza NE, Visentainer JV. Ácidos graxos poliinsaturados ômega-3 e ômega-6: importância e ocorrência em alimentos. Rev. Nutr 2006; 19:761-70. (Pubitemid 46409564)
30. Nordic Council of Ministers. Nordic nutrition recommendations. Scand J Nutr 1996; 40:161-5.
31. Chardigny JM, Bretillon L, Sébédio JL. New insights in health effects of trans alpha-linolenic acid isomers in humans. Eur J Lipid Sci Technol 2001; 103:478-82.
32. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, et al. Polynsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71 (Suppl 1):179-88.
33. World Health Organization. Joint Consultation: fats and oils in human nutrition. Nutr Rev 1995; 53:202-5.
34. Simopoulos AP. Omega-6/Omega-3 essential fatty acid ratio and chronic diseases. Food Rev Inter 2004; 20:77-90. (Pubitemid 38474536)
35. Simopoulos AP. Omega-3 fatty acids in wild plants, nuts and seeds. Ásia Pacific J Clin Nutr 2002; 11:163-73.
36. Institute of Medicine. National Research Council. Dietary Intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macrontrients). Washington (DC): National Academy Press; 2002.
37. Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS. Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 2009; 40:3485-92.
38. Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther 2009; 26:675-90.
39. Bouwens M, Van De Rest O, Dellschaft N, Bromhaar MG, De Groot LC, Geleijnse JM, Müller M, Afman LA. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009; 90:415-24.
40. Kris-Etherton PM, Innis S, Ammerican Dietetic Assocition, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007; 107:1599-611.
41. Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 2007; 85:1171-84. (Pubitemid 46740457)
42. Jiang ZM, Wilmore DW, Wang XR, Wei JM, ZhanG ZT, Gu ZY, Wang S, Han SM, Jiang H, Yu K. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg 2010; 97:804-9.
43. Levy BD, Lukacs NW, Berlin AA, Schimidt B, Guilford WJ, Serhan CN. Lipotoxin A4 anlogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. Faseb J 2007; 21: 3877-84. (Pubitemid 350232345)
44. Marcheselli VL, Hong S, Lukiw WJ, Hua Tian X, Gronert K. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-17. (Pubitemid 37346009)
45. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A. A role for docosahexaenoic acid-derived neuriprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-83. (Pubitemid 41434404)
46. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med 2010; 268:15-24.
47. Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006; 58:463-87. (Pubitemid 44394909)
48. Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN. Resolvin E1 metabolome in local inactivation during inflammation resolution. J Immunol 2008; 180: 3512-9.
49. González-Périz A, Clària J. Resolution of adipose tissue inflammation. Scientific World Journal 2010; 10:832-56.
50. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010; 16:592-7.
51. Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Rev 2007; 56: 443- 71.
52. Shwab JM,Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-74 (Pubitemid 46920139)
53. Coelho-Castelo AAM, Trombone APP, Rocha CD, Lorenzo JCC. Resposta imune a doenças infecciosas. Medicina (Ribeirão Preto) 2009; 42:127-142.
54. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, Cheng G, VON Andrian UH, Serhan CN.Resolvin E1, an EPA-derived mediator in whole blood, selectively counter-regulates leukocytes and platelets. Blood 2008; 112:848-55.
55. Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009; 158:947-59.
56. Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, De Souza PM, Gilroy DW. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc Natl Acad Sci U S A 2010; 107:8842-7.
57. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, Asano K, Ishizaka A, Takeda J, Levy BD. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 2010; 184:836-43.